about
Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 DiabetesReduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or MetforminA genome-wide association study identifies a novel major locus for glycemic control in type 1 diabetes, as measured by both A1C and glucoseHeart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial.Pilot genome-wide association search identifies potential loci for risk of erectile dysfunction in type 1 diabetes using the DCCT/EDIC study cohort.Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet dataImpact of C-peptide preservation on metabolic and clinical outcomes in the Diabetes Control and Complications Trial.Application of robust estimating equations to the analysis of quantitative longitudinal data.Large sample inference for a win ratio analysis of a composite outcome based on prioritized components.Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy.Some large-sample distribution-free estimators and tests for multivariate partially incomplete data from two populations.Conflicts of interest in data monitoring of industry versus publicly financed clinical trials.Parametric survival models for interval-censored data with time-dependent covariates.Rosiglitazone decreases C-reactive protein to a greater extent relative to glyburide and metformin over 4 years despite greater weight gain: observations from a Diabetes Outcome Progression Trial (ADOPT)Failure to preserve beta-cell function with mycophenolate mofetil and daclizumab combined therapy in patients with new- onset type 1 diabetesEffect of prior intensive insulin treatment during the Diabetes Control and Complications Trial (DCCT) on peripheral neuropathy in type 1 diabetes during the Epidemiology of Diabetes Interventions and Complications (EDIC) StudyRationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™)A flexible stochastic curtailing procedure for the log-rank test.Development and progression of renal insufficiency with and without albuminuria in adults with type 1 diabetes in the diabetes control and complications trial and the epidemiology of diabetes interventions and complications study.Comparison of urinary albumin-creatinine ratio and albumin excretion rate in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study.Randomization in clinical trials: conclusions and recommendations.Type 1 Diabetes TrialNet--an international collaborative clinical trials networkSample size requirements for studies of treatment effects on beta-cell function in newly diagnosed type 1 diabetes.A comparison of the baseline metabolic profiles between Diabetes Prevention Trial-Type 1 and TrialNet Natural History Study participants.Insulin secretion measured by stimulated C-peptide in long-established Type 1 diabetes in the Diabetes Control and Complications Trial (DCCT)/ Epidemiology of Diabetes Interventions and Complications (EDIC) cohort: a pilot study.Renal outcomes in patients with type 1 diabetes and macroalbuminuriaPower of the Mantel-Haenszel and other tests for discrete or grouped time-to-event data under a chained binomial model.Applications of the Wei-Lachin multivariate one-sided test for multiple outcomes on possibly different scales.Costs associated with the primary prevention of type 2 diabetes mellitus in the diabetes prevention program.Levels of oxidized LDL and advanced glycation end products-modified LDL in circulating immune complexes are strongly associated with increased levels of carotid intima-media thickness and its progression in type 1 diabetes.Progression of carotid artery intima-media thickness during 12 years in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study.Oxidized LDL immune complexes and coronary artery calcification in type 1 diabetes.Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT).Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.Skin advanced glycation end products glucosepane and methylglyoxal hydroimidazolone are independently associated with long-term microvascular complication progression of type 1 diabetes.Validity of self-report in type 1 diabetic subjects for laser treatment of retinopathyLong-term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: an analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications cohort.Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy.Effect of intensive diabetes therapy on the progression of diabetic retinopathy in patients with type 1 diabetes: 18 years of follow-up in the DCCT/EDIC
P50
Q22250887-D3B40290-C2AF-4EC3-BDAE-B625A90B9145Q22250892-4DD9CB6E-6D99-4421-A841-535A8172363EQ24642266-CCAE047B-047C-4C9D-BAD8-3CBAE109D9C0Q27301948-0A8D935A-AA54-492A-9B89-A44D05FF892FQ29417092-4DC70828-EE40-41B8-AC9D-D8D714F12C3FQ30521476-45DD1169-8BBE-4F64-8D42-0C41EE158A01Q30567434-C9A94416-EA73-4B75-A96E-83E4F9B7845EQ30667009-12A73601-5F96-434D-9711-2624E4FDA6BCQ30689191-7A90C12A-CD3D-435E-8B4B-12B8BA6F5F20Q30837772-4A807580-151E-4A85-9515-422E08413F95Q30922892-8057A9A5-054E-4653-AC6B-C3845008C8FBQ30927791-47FEB7E2-0AF4-43E5-B82C-C65ED4D8BD9BQ31036205-0D24CE07-CD41-42D4-A801-88D651237C0CQ33556796-2F172ABA-FB69-4A1A-B93B-247C374ADF86Q33751549-4DD846D5-EBC0-460C-9E93-C989652B90EDQ33804684-B7216257-30A0-4D7E-AB40-9128937413E4Q33812170-14C31ABB-349C-4F8C-A9B2-273BCAB77819Q33920263-942D065E-C43A-4396-9E29-C2CBA35D784CQ33932739-A5E3CD5C-7BBB-4A92-BAB3-9FDBCE447793Q33944806-05789056-BD16-4BB3-8D6C-A5D643869FA7Q34049227-0C0DE39A-1B7B-4ED7-9F6E-34463A5B60FDQ34055005-E58682E7-0B84-4AF8-B472-96C17F04E34DQ34079225-E913E473-2AD9-479E-AF04-DF2C0E106492Q34200419-83EE1C8B-9543-4570-9E34-F5401CD6F8D6Q34207348-AC9ACCBD-E354-4D9A-B98A-771EDA733848Q34260068-5E3E973D-1493-409D-ADFF-F347D4147257Q34341169-5C45BCB7-19A0-4DAE-A5BA-1B7314D16571Q34361859-65BB8822-6A70-4F2A-ABF3-54F5DE74AF85Q34451051-AE14C30F-FA89-4630-B6E1-15F0FABE316CQ34527165-36E3576A-499E-447C-8E11-462EB03FF2D2Q34527201-8DE1E251-FE48-4AB8-9D5E-DA1F802593B4Q34542912-CE58E914-8E40-4AEA-8EC9-E469BEF33C8CQ34587610-7602CEC1-CDF8-474B-A353-48D524D2A097Q34670462-093F81E2-E883-4D6A-9D9D-0F18FDC0152FQ34673134-B65735C3-0E49-4B1B-B2CD-ACA9113CC690Q34762475-6621BCE0-DF17-4ED4-8416-AD1CEA3001B0Q34869372-74B45EE8-A6F2-4D52-A8A1-97D794572FFDQ34891831-9A5AA7C4-852B-4E82-92A4-9C4DBB3E594BQ34926845-F93A6703-1EE5-4F84-8C00-E07BDD669A55Q35004314-853BF62D-68DC-4489-96D1-5C6AB667BB96
P50
subject
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
ricercatore
@it
հետազոտող
@hy
name
John M Lachin
@nl
John M Lachin
@sl
John M. Lachin
@en
John M. Lachin
@es
type
label
John M Lachin
@nl
John M Lachin
@sl
John M. Lachin
@en
John M. Lachin
@es
altLabel
John Lachin
@en
prefLabel
John M Lachin
@nl
John M Lachin
@sl
John M. Lachin
@en
John M. Lachin
@es
P1006
P214
P244
P5361
P1006
P106
P1153
18536024000
P21
P213
0000 0001 1050 5780
P214
P244
P31
P496
0000-0001-9838-2841
P5361
LachinJohnM1942-
P569
1942-07-04T00:00:00Z
P735
P7859
lccn-n82060410